Centro Ricerca Tettamanti Pediatrics Fondazione MBBM San Gerardo Hospital University of Milano Bicocca University of Milano Bicocca Monza Italy

Faculty of Science National Centre for Biomolecular Research Masaryk University Brno Czech Republic

Genetics University of Milano Bicocca Monza Italy

Pediatrics Fondazione MBBM San Gerardo Hospital University of Milano Bicocca Italy

Zobrazit více v PubMed

Nucifora G, Laricchia-Robbio L, Senyuk V. EVI1 and hematopoietic disorders: history and perspectives. Gene. 2006;368:1–11. PubMed

Lugthart S, Gröschel S, Beverloo HB, et al. Clinical, molecular, and prognostic significance of WHO type inv(3)(q21q26.2)/t(3;3)(q21;q26.2) and various other 3q abnormalities in acute myeloid leukemia. J Clin Oncol. 2010;28:3890–3898. PubMed

De Braekeleer M, Le Bris MJ, De Braekeleer E, et al. 3q26/EVI1 rearrangements in myeloid hemopathies: a cytogenetic review. Future Oncol. 2015;11:1675–1686. PubMed

Barjesteh van Waalwijk van Doorn-Khosrovani S, Erpelinck C, van Putten WL, et al. High EVI1 expression predicts poor survival in acute myeloid leukemia: a study of 319 de novo AML patients. Blood. 2003;101:837–845. PubMed

Balgobind BV, Lugthart S, Hollink IH, et al. EVI1 overexpression in distinct subtypes of pediatric acute myeloid leukemia. Leukemia. 2010;24:942–949. PubMed

Li F, He W, Geng R, et al. Myeloid leukemia with high EVI1 expression is sensitive to 5-aza-2’-deoxycytidine by targeting miR-9. Clin Transl Oncol. 2020;22:137–143. PubMed

Wanquet A, Prebet T, Berthon C, et al. Azacitidine treatment for patients with myelodysplastic syndrome and acute myeloid leukemia with chromosome 3q abnormalities. Am J Hematol. 2015;90:859–863. PubMed

Mittal N, Li L, Sheng Y, et al. A critical role of epigenetic inactivation of miR-9 in EVI1 high pediatric AML. Mol Cancer. 2019;18:1–6. PubMed PMC

Glass C, Wilson M, Gonzalez R, et al. The role of EVI1 in myeloid malignancies. Blood Cells Mol Dis. 2014;53:67–76. PubMed

Bindels EM, Havermans M, Lugthart S, et al. EVI1 is critical for the pathogenesis of a subset of MLL-AF9, rearranged AMLs. Blood. 2012;119:5838–5849. PubMed PMC

Bobadilla D, Enriquez EL, Alvarez G, et al. An interphase fluorescence in situ hybridisation assay for the detection of 3q26.2/EVI1 rearrangements in myeloid malignancies. Br J Haematol. 2007;136:806–813. PubMed

Haferlach C, Bacher U, Grossmann V, et al. Three novel cytogenetically cryptic EVI1 rearrangements associated with increased EVI1expression and poor prognosis identified in 27 acute myeloid leukemia cases. Genes Chromosomes Cancer. 2012;51:1079–1085. PubMed

Canaani J, Labopin M, Itälä-Remes M, et al. Prognostic significance of recurring chromosomal abnormalities in transplanted patients with acute myeloid leukemia. Leukemia. 2019;33:1944–1952. PubMed

Grioni A, Fazio G, Rigamonti S, et al. A Simple RNA target capture NGS strategy for fusion genes assessment in the diagnostics of pediatric B-cell acute lymphoblastic leukemia. HemaSphere. 2019;3:1–9. PubMed PMC

Brown CA, Youlden DR, Aitken JF, et al. Therapy-related acute myeloid leukemia following treatment for cancer in childhood: a population-based registry study. Pediatr Blood Cancer. 2018;65:1–7. PubMed